Potential Use of Nitrogen-Doped Carbon Nanotube Sponges as Payload Carriers Against Malignant Glioma
Glioblastoma is the most aggressive brain tumor with a low median survival of 14 months. The only Food and Drug Administration (FDA)-approved treatment for topical delivery of the cancer drug carmustine is Gliadel. However, its use has been associated with several side-effects, mainly provoked by a...
Main Authors: | Alelí Salazar, Verónica Pérez-de la Cruz, Emilio Muñoz-Sandoval, Víctor Chavarria, María de Lourdes García Morales, Alejandra Espinosa-Bonilla, Julio Sotelo, Anabel Jiménez-Anguiano, Benjamín Pineda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Nanomaterials |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-4991/11/5/1244 |
Similar Items
-
An Outcomes Analysis of Carmustine Wafers with Surgery versus Placebo Wafers with Surgery in the Treatment of Glioblastoma Multiforme
by: Yamauchi, Phillip
Published: (2007) -
Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy
by: Kleinberg L
Published: (2016-11-01) -
Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis
by: Zhi-Ze Xiao, et al.
Published: (2020-09-01) -
Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy
by: Steffi Urbschat, et al.
Published: (2017-05-01) -
Prognostic effects of O6-Methylguanine DNA methyltransferase promoter hypermethylation in high-grade glioma patients with carmustine wafer implants
by: Mao-Yu Chen, et al.
Published: (2017-01-01)